drugset / Trial / NCT02574923

Outcomes of Stem Cells for Cerebral Palsy

NCT02574923

Phase 2 Completed 30 enrolled Vinmec Healthcare System
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cells in patients with cerebral palsy.

Timeline

Start
2015-11-05
Primary completion
2018-03-30
Completion
2018-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy Intrathecal

Indications